Trial Profile
An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Zamicastat (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors BIAL - Portela C S.A.
- 29 Oct 2021 Status changed from recruiting to completed.
- 05 Oct 2021 This trial has been completed in Austria.
- 15 Aug 2021 This trial has been completed in Germany, according to European Clinical Trials Database record.